These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31389822)

  • 21. Seventh try's a charm: ventricular fibrillation terminated by the seventh shock.
    Li J; Zitron E; Katus HA; Becker R
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):e4-6. PubMed ID: 21505170
    [No Abstract]   [Full Text] [Related]  

  • 22. Dual defibrillation for refractory ventricular fibrillation in a patient with a left ventricular assist device.
    Fender E; Tripuraneni A; Henrikson CA
    J Heart Lung Transplant; 2013 Nov; 32(11):1144-5. PubMed ID: 23953919
    [No Abstract]   [Full Text] [Related]  

  • 23. Implantable Cardioverter-Defibrillators and Wearable Defibrillators: Guidelines and Updates.
    Mathuria N
    Tex Heart Inst J; 2020 Feb; 47(1):51-52. PubMed ID: 32148457
    [No Abstract]   [Full Text] [Related]  

  • 24. Circumventing a left ventricular assist device and implantable cardioverter defibrillator interaction: an alternative method of shielding.
    Guise KD; Franconame F; Chung EH
    Europace; 2013 Dec; 15(12):1689. PubMed ID: 23608031
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transvenous ICD lead malposition in the left ventricle: long-term follow-up.
    Franck H; Wollschläger H
    Clin Res Cardiol; 2013 Feb; 102(2):159-61. PubMed ID: 22868694
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database.
    Lunati M; Proclemer A; Boriani G; Landolina M; Locati E; Rordorf R; Daleffe E; Ricci RP; Catanzariti D; Tomasi L; Gulizia M; Baccillieri MS; Molon G; Gasparini M;
    Europace; 2016 Sep; 18(9):1391-8. PubMed ID: 26826135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators.
    Bansal N; Szpiro A; Masoudi F; Greenlee RT; Smith DH; Magid DJ; Gurwitz JH; Reynolds K; Tabada GH; Sung SH; Dighe A; Cassidy-Bushrow A; Garcia-Montilla R; Hammill S; Hayes J; Kadish A; Sharma P; Varosy P; Vidaillet H; Go AS
    Heart; 2017 Apr; 103(7):529-537. PubMed ID: 27742796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained ventricular fibrillation in an alert patient: preserved hemodynamics with a left ventricular assist device.
    Patel P; Williams JG; Brice JH
    Prehosp Emerg Care; 2011; 15(4):533-6. PubMed ID: 21806468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repetitive shock therapy of subcutaneous implantable cardioverter defibrillators in a patient with idiopathic ventricular fibrillation: What is the mechanism?
    Hasegawa K; Miyazaki S; Ishikawa E; Mukai M; Aoyama D; Nodera M; Kaseno K; Tada H
    J Cardiovasc Electrophysiol; 2019 Oct; 30(10):2121-2124. PubMed ID: 31332856
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
    Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia in patients with an implantable defibrillator warrants catheter ablation.
    Kuck KH
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):713-20; discussion 720. PubMed ID: 20009082
    [No Abstract]   [Full Text] [Related]  

  • 34. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
    J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporal associations between thoracic volume overload and malignant ventricular arrhythmias: a study of intrathoracic impedance.
    Ip JE; Cheung JW; Park D; Hellawell JL; Stein KM; Iwai S; Liu CF; Lerman BB; Markowitz SM
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):293-9. PubMed ID: 20946226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices.
    Enriquez AD; Calenda B; Miller MA; Anyanwu AC; Pinney SP
    Circ Arrhythm Electrophysiol; 2013 Aug; 6(4):668-74. PubMed ID: 23873139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ventricular fibrillation undersensing due to air entrapment in a patient implanted with a subcutaneous cardioverter defibrillator.
    Adduci C; Spadoni L; Palano F; Francia P
    J Cardiovasc Electrophysiol; 2019 Aug; 30(8):1373-1374. PubMed ID: 31165543
    [No Abstract]   [Full Text] [Related]  

  • 38. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 39. Diathermy-induced ventricular fibrillation with Riata high-voltage lead insulation failure.
    Gunaruwan P; Barlow M
    Europace; 2013 Apr; 15(4):473. PubMed ID: 22872605
    [No Abstract]   [Full Text] [Related]  

  • 40. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry.
    Tsai VW; Cooper J; Garan H; Natale A; Ptaszek LM; Ellinor PT; Hickey K; Downey R; Zei P; Hsia H; Wang P; Hunt S; Haddad F; Al-Ahmad A
    Circ Heart Fail; 2009 May; 2(3):197-201. PubMed ID: 19808340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.